PTC299

Description: PTC-299 (PTC299; PTC 299) is a novel, potent and orally bioavailable VEGF inhibitor with potential antiangiogenesis and antineoplastic activities. It acts via posttranscriptional regulation of VEGF mRNA under conditions of cellular stress. PTC299 has broad and potent activity against hematological cancer cells. PTC299 targets post-transcriptionally by selectively binding the 5'- and 3'-untranslated regions (UTR) of VEGF messenger RNA (mRNA), thereby preventing translation of VEGF. This inhibits VEGF protein production and decreases its levels in the tumor and bloodstream. In turn, this may result in the inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and eventually the induction of tumor cell death.

References: Mol Cancer Ther. 2019 Jan; 18(1):3-16.; J Acquir Immune Defic Syndr. 2016 May 1; 72(1):52-7.